Buccheri G, Ferrigno D
A. Carle Hospital of Chest Diseases, Cuneo, Italy.
Lung Cancer. 1996 Jun;14(2-3):281-300. doi: 10.1016/0169-5002(96)00554-5.
The optimal treatment for regionally advanced non-small cell lung cancer (NSCLC, Stage IIIa/IIIb) remains unknown. Proposed approaches include surgery, radiotherapy, chemotherapy, and combinations of these. No treatment modality, however, has ever shown other than modest or minimal beneficial effects. When differences between new and old treatments appear trivial, as in the management of the locally advanced NSCLC, controlled studies are necessary to select the best approach. This review is based on a systematic overview of data from randomized trials comparing different treatment modalities. The following six points emerged from the cited literature. (1) It is sufficiently proved that chemotherapy alone prolongs survival in patients with both locally advanced and metastatic disease. (2) Although it is probably true that radiation therapy is better than no active treatment, this idea is supported by very limited evidence. (3) Although it is probably also true that radiotherapy alone is not worse than chemotherapy alone, this is another insufficiently proved issue. (4) The possible superiority of chemo-radiotherapy to chemotherapy alone or to supportive care is also poorly documented. (5) There is abundant evidence that chemo-radiotherapy is better than radiotherapy alone (however, this information may be unhelpful if point 2, or 3 remains unclarified). (6) Although neoadjuvant treatments have improved resectability and may ensure overall better results, the surgical cure, either alone or in combination with chemotherapy or chemo-radiotherapy, is another unproved option. Based on the above six points, it was concluded that new randomized studies are urgently needed to confirm the possible superiority of chemo-radiotherapy to chemotherapy. Only after such a validation, will the many ongoing trials, designed to prove the possible superiority of local surgical control to the more traditional approaches based on thoracic irradiation, have a practical sense.
局部晚期非小细胞肺癌(NSCLC,Ⅲa/Ⅲb期)的最佳治疗方案仍不明确。建议的治疗方法包括手术、放疗、化疗以及这些方法的联合应用。然而,没有一种治疗方式显示出除了适度或极小的有益效果之外的其他效果。当新老治疗方法之间的差异似乎微不足道时,如在局部晚期NSCLC的治疗中,就需要进行对照研究以选择最佳治疗方法。本综述基于对比较不同治疗方式的随机试验数据的系统概述。从引用的文献中得出了以下六点。(1)有充分证据表明,单纯化疗可延长局部晚期和转移性疾病患者的生存期。(2)虽然放疗可能优于无积极治疗这一点可能是正确的,但这一观点的证据非常有限。(3)虽然单纯放疗可能也不比单纯化疗差这一点可能也是正确的,但这也是一个证据不足的问题。(4)放化疗相对于单纯化疗或支持治疗可能具有的优势也缺乏充分记录。(5)有大量证据表明放化疗优于单纯放疗(然而,如果第2点或第3点仍未明确,此信息可能无济于事)。(6)虽然新辅助治疗提高了可切除性并可能确保总体上有更好的结果,但单独手术治愈或与化疗或放化疗联合手术治愈仍是另一个未经证实的选择。基于以上六点,得出结论认为迫切需要新的随机研究来证实放化疗相对于化疗可能具有的优势。只有在进行这样的验证之后,许多旨在证明局部手术控制相对于基于胸部放疗的更传统方法可能具有的优势的正在进行的试验才具有实际意义。